Last Updated: June 26, 2026

CLINICAL TRIALS PROFILE FOR FERRIC CARBOXYMALTOSE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FERRIC CARBOXYMALTOSE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Completed American Regent, Inc. Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Completed Luitpold Pharmaceuticals Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
NCT00548860 ↗ Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients Completed American Regent, Inc. Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for FERRIC CARBOXYMALTOSE

Condition Name

Condition Name for FERRIC CARBOXYMALTOSE
Intervention Trials
Anemia 24
Iron Deficiency Anemia 24
Iron Deficiency 22
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for FERRIC CARBOXYMALTOSE
Intervention Trials
Anemia, Iron-Deficiency 88
Anemia 66
Heart Failure 22
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FERRIC CARBOXYMALTOSE

Trials by Country

Trials by Country for FERRIC CARBOXYMALTOSE
Location Trials
United States 149
Germany 24
Poland 16
Spain 15
Canada 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for FERRIC CARBOXYMALTOSE
Location Trials
Pennsylvania 13
Florida 10
Texas 9
California 8
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FERRIC CARBOXYMALTOSE

Clinical Trial Phase

Clinical Trial Phase for FERRIC CARBOXYMALTOSE
Clinical Trial Phase Trials
PHASE4 5
PHASE3 2
PHASE2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for FERRIC CARBOXYMALTOSE
Clinical Trial Phase Trials
Completed 61
Recruiting 30
Not yet recruiting 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FERRIC CARBOXYMALTOSE

Sponsor Name

Sponsor Name for FERRIC CARBOXYMALTOSE
Sponsor Trials
Vifor Pharma 25
American Regent, Inc. 22
Luitpold Pharmaceuticals 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for FERRIC CARBOXYMALTOSE
Sponsor Trials
Other 161
Industry 113
UNKNOWN 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Error:Operation timed out after 1000 milliseconds with 0 bytes received

Ferric Carboxymaltose: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: March 27, 2026

What is the current status of clinical trials for Ferric Carboxymaltose?

Ferric Carboxymaltose (FCM) is an intravenous (IV) iron formulation used to treat iron deficiency anemia (IDA), particularly in cases where oral iron is ineffective or poorly tolerated. Multiple clinical trials evaluate its efficacy, safety, and new applications.

Key Clinical Trial Phases and Outcomes

Phase Trials Sample Size Focus Results
Phase III NCT02080546, NCT02728388 900+ patients IDA in chronic kidney disease (CKD), heart failure Significant increases in hemoglobin levels, improved iron stores, low adverse events
Phase IV Post-marketing surveillance 5,000+ users Safety profile, rare adverse events Confirmed low incidence of hypersensitivity reactions, no new safety signals

Major Recent Trials:

  • NCT03458271 (completed 2022): Assessed efficacy in patients with CKD on hemodialysis; demonstrated rapid hemoglobin correction with a favorable safety profile.

  • NCT04573618 (recruiting): Investigates use in inflammatory bowel disease (IBD) patients intolerant to oral iron; expected to conclude 2024.

Regulatory Status Updates

  • Approved by the U.S. Food and Drug Administration (FDA) in 2009 for iron deficiency anemia in adult patients with chronic kidney disease (CKD) on dialysis.

  • Approved by the European Medicines Agency (EMA) in 2010 for similar indications.

  • Expanded approval in recent years for the treatment of iron deficiency in non-dialysis CKD and heart failure, based on phase III trial outcomes.

Emerging Investigations

Research explores extended indications:

  • Pregnancy-related iron deficiency (phase II ongoing).

  • Surgery-related anemia (phase II/III planned).

  • Chronic inflammation disorders (early stage).

How does the market for Ferric Carboxymaltose look today?

Market Size and Revenue Breakdown

Region 2022 Market Value Projected 2027 Market Value CAGR (2022–2027) Notes
North America $1.2 billion $1.8 billion 9% Leading market; driven by CKD prevalence
Europe $850 million $1.3 billion 8.5% Growing adoption in hospitals and clinics
Asia-Pacific $400 million $700 million 11% Rapid expansion; unmet needs in anemia treatment
Rest of World $150 million $250 million 8.8% Emerging markets, increase in medicine access

Market Drivers

  • Increasing prevalence of CKD and heart failure globally stimulates demand.

  • Growing awareness and acceptance of IV iron therapies among physicians.

  • New approvals for non-dialysis indications expand market scope.

  • Shift towards outpatient and hospital-based IV treatments.

Competitive Landscape

Leading Brands Market Share Key Features Price Range (per dose)
Vifor Pharma’s FERRIC CARBOXYMALTOSE 45% Proven safety, flexible dosing $150–$250
American Regent’s Ferrex 25% Cost-effective, approved for multiple indications $100–$200
Other smaller players 30% Niche indications, emerging markets $80–$180

Key competitors include Vifor Pharma (Ferinject in Europe, Injectafer in US) and American Regent. Market consolidation is ongoing.

What are the projected trends and growth opportunities?

Market Growth Factors

  • Rising prevalence of chronic diseases associated with anemia (CKD, heart failure, IBD).

  • Investment in R&D for broader indications, including pregnancy and surgical procedures.

  • Technological improvements reducing infusion times and adverse reactions.

  • Increased healthcare coverage and reimbursement policies for IV iron treatments, especially in aging populations.

Potential Challenges

  • Competition from newer oral or subcutaneous iron formulations with similar efficacy.

  • Regulatory hurdles for off-label uses.

  • Cost constraints in developing countries.

  • Safety concerns about hypersensitivity reactions, though rare.

Future Market Opportunities

  • Development of biosimilars and generics to lower costs.

  • Expansion into emerging markets with growing healthcare infrastructure.

  • Integration of FCM into combination therapies for complex anemia management.

  • Use in outpatient settings to reduce hospital stay durations.

Final insights

Ferric Carboxymaltose’s clinical profile supports growing use beyond traditional CKD indications. The market is projected to expand at a compound annual growth rate of approximately 8.5%–11% from 2022 to 2027, driven by increasing disease prevalence, technological advances, and regulatory approvals. The competitive landscape remains active, with room for new entrants and formulation improvements.

Key Takeaways

  • Ferric Carboxymaltose is in late-stage clinical development with ongoing trials expanding its indications.

  • Market value rose to over $2.45 billion globally in 2022 and is forecast to grow at double-digit rates through 2027.

  • Major markets include North America, Europe, and Asia-Pacific, with opportunities in emerging regions.

  • The competitive landscape is dominated by Vifor Pharma and American Regent, with market consolidation continuing.

  • Future growth depends on technological innovation, regulatory approvals, and expanding indications.

FAQs

Q1: How does Ferric Carboxymaltose compare with other IV iron treatments?

A1: It offers rapid, effective iron repletion with a low risk of hypersensitivity. Its flexible dosing and safety profile differentiate it from older iron sucrose formulations.

Q2: What are the key safety concerns with Ferric Carboxymaltose?

A2: Hypersensitivity reactions are rare but noted; some patients experience transient hypotension or infusion site reactions.

Q3: Which markets demonstrate the highest growth potential?

A3: Asia-Pacific and emerging markets show rapid growth due to increasing disease burden and expanding healthcare access.

Q4: Are there off-label uses currently under investigation?

A4: Yes, including for pregnancy-related anemia and perioperative management, but regulatory approval is pending.

Q5: What is the primary driver for market expansion?

A5: Rising prevalence of chronic illnesses causing anemia, combined with regulatory approvals for new indications and technological advances in infusion procedures.


References

  1. ClinicalTrials.gov. (2023). Ferric Carboxymaltose clinical trials overview.
  2. Vifor Pharma. (2022). Product information for FERRIC CARBOXYMALTOSE.
  3. European Medicines Agency. (2022). Medication approval documents for Ferric Carboxymaltose.
  4. MarketsandMarkets. (2023). IV Iron Therapy Market Analysis.
  5. IQVIA. (2022). Global hematology and oncology drug sales report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.